AUS
NZ
UK
CA
USA
IND
Highlights
- ResMed’s Market Movement: Shares of ResMed (RMD) have declined by 4.6% since the start of 2025.
- Healthcare Industry Resilience: The sector is known for its stable revenue streams and growth potential.
- Valuation Insights: Current price-to-sales ratio suggests shares are trading below historical averages.
Founded in 1989 in Australia, ResMed (ASX:RMD) has evolved into a global leader in medical equipment, with headquarters in San Diego, California. Specializing in sleep and respiratory care, ResMed is well known for its cloud-connected continuous positive airway pressure (CPAP) machines designed to treat obstructive sleep apnea (OSA). The company operates in over 140 countries and employs more than 10,000 professionals worldwide.
ResMed’s business is divided into two core segments: Sleep and Respiratory Care, and Software as a Service (SaaS). The Sleep and Respiratory Care division focuses on providing CPAP devices, non-invasive ventilation, and other life-support solutions. Meanwhile, the SaaS unit enhances healthcare services through its software platforms, supporting durable medical equipment (DME/HME) management. By integrating software with hardware, ResMed has built a comprehensive digital health network, leveraging cloud-based insights to improve patient outcomes and optimize healthcare costs.
Why Healthcare Stocks Continue to Gain Attention
The S&P/ASX 200 Healthcare Index (ASX:XHJ) has delivered an annualized return of 1.80% over the past five years, compared to 11.74% from the broader ASX 200. Despite its modest sector-wide performance, healthcare remains a fundamental industry with strong long-term prospects. Here are three key factors driving interest in the sector:
- Consistent Revenue Streams
Healthcare remains an essential expense, making it resilient even during economic downturns. Unlike industries tied to commodity prices or seasonal trends, healthcare companies benefit from steady demand. Historical trends indicate that healthcare was the best-performing sector during the global financial crisis (GFC), highlighting its defensive qualities.
- Expanding Growth Opportunities
The global healthcare market, particularly in the U.S., is projected to grow substantially. U.S. healthcare spending, which accounts for over 40% of global expenditure, is expected to expand by 7% annually from 2022 to 2027, reaching an estimated US$819 billion. Certain sub-sectors, such as healthcare IT and SaaS-based solutions, are forecast to grow even faster, at rates exceeding 15% annually from 2024 to 2030.
- Increasing Interest in Ethical Investments
Investor focus on sustainable and ethical investments has been rising. A recent survey found that over half of investors plan to increase allocations to sustainable sectors in 2024. Given its role in providing essential healthcare solutions, ResMed aligns well with this trend, making it an attractive option for those prioritizing socially responsible investments.
Understanding ResMed’s Valuation
From a valuation perspective, ResMed’s shares currently trade at a price-to-sales (P/S) ratio of 4.62x, which is below its five-year average of 8.70x. This suggests that the stock is trading at a lower multiple compared to historical levels. This shift could be due to either a decline in the share price or growth in revenue. Notably, ResMed has demonstrated revenue growth over the past three years, indicating continued business expansion.
While valuation metrics provide valuable insights, they should always be analyzed within a broader market context. Many factors influence stock prices, including industry trends, economic conditions, and company-specific performance.
Final Thoughts
ResMed’s (RMD) combination of innovative healthcare solutions, a stable revenue model, and increasing global demand for medical technologies positions it as a key player in the sector. The healthcare industry remains an area of interest for many due to its defensive nature and potential for long-term growth. As global healthcare spending continues to rise, companies with strong digital integration and essential medical offerings could remain well-positioned in the evolving market landscape.
